News
The agency granted the accelerated approval for Datroway in EGFR-mutant NSCLC based on data from the TROPION-Lung05 and TROPION-Lung01 trials.
The funding comes from the Foundation Fighting Blindness' venture philanthropy arm, the Retinal Degeneration Fund.
Top-line results from a Phase III trial showed an overall survival benefit for zanzalintinib combo therapy in microsatellite-stable colorectal cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback